证券代码：300676 证券简称：华大基因 公告编号：2025-058 深圳华大基因股份有限公司 一、关联交易概述 （一）随着全球公共卫生形势日趋复杂与传染病谱的持续演变，病原体快速 识别已成为公共卫生防控体系的关键环节与临床诊疗的迫切需求。为有效应对上 述挑战，构建具备自主知识产权、快速响应能力与高准确性的病原体检测整体解 决方案，充分发挥上市公司与医疗机构、高等院校等机构在科研、人才及产业资 源方面的协同优势，共同推进该领域相关技术的联合攻关与创新突破，深圳华大 基因股份有限公司（以下简称公司、上市公司）的全资子公司天津华大医学检验 所有限公司（以下简称天津医检所）拟与关联方杭州华大生命科学研究院（以下 简称杭州华大研究院）、常州新一产生命科技有限公司（以下简称常州新一产） 及其他大专院校、研究所、医院共计十家机构，联合申报"新发突发与重大传染 病防控国家科技重大专项"中的"病原体检测专用便捷长读长测序系统开发"项 目（以下简称联合申报项目）。 本联合申报项目总经费人民币 12,000 万元（以下万元均指人民币万元），其 中，申请国拨经费 2,000 万元，联合申报单位自筹经费 10,000 万元。自筹经 ...

证券代码：300676 证券简称：华大基因 公告编号：2025-062 深圳华大基因股份有限公司 关于 2025 年前三季度计提信用减值损失、资产减值损失和核销 资产的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司）根据《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》《企业会计准则》及公司相 关会计制度的规定，对截至 2025 年 9 月 30 日合并财务报表范围内相关资产计提 减值准备及核销。现将相关情况公告如下： 一、本次计提信用减值损失、资产减值损失和核销资产的概述 为更加真实、准确地反映公司截至 2025 年 9 月 30 日的财务状况、资产价值 及经营成果，基于谨慎性原则，公司对合并报表范围内截至 2025 年 9 月 30 日的 应收账款、其他应收款、存货、固定资产等各类资产进行了全面清查，对各项资 产减值的可能性进行了充分的评估和分析，对存在减值迹象的资产计提相应减值 准备。 （一）计提信用减值损失及资产减值损失的资产范围和金额 公司 2025 年 1-9 月计提信用减值和 ...

证券代码：300676 证券简称：华大基因 公告编号：2025-059 深圳华大基因股份有限公司 关于 2026 年度开展外汇套期保值业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、交易额度及期限：深圳华大基因股份有限公司（以下简称公司）为提高公司应 对外汇波动风险的能力，降低汇率大幅波动对公司业绩的影响，增强财务稳健性，公司 及合并报表范围内的子公司 2026 年度拟继续与具有外汇套期保值业务经营资质的金融 机构开展外汇套期保值业务，交易品种包括但不限于远期结售汇、外汇掉期、外汇期权 等产品或上述产品的组合；预计任一交易日持有的最高合约价值不超过人民币 10 亿元 或等值外币（含本数，下同）。该额度自 2026 年 1 月 1 日至 2026 年 12 月 31 日的 12 个月内有效，在授权期限内可循环滚动使用。 2、已履行的审议程序：本事项已经公司第四届董事会第七次会议和第四届监事会 第七次会议审议通过，根据《深圳证券交易所上市公司自律监管指引第 7 号——交易与 关联交易》的规定，本议案尚需提交公司 2025 年第二次临 ...

证券代码：300676 证券简称：华大基因 公告编号：2025-061 深圳华大基因股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《深圳华大基因股份有限公司章程》（以 下简称《公司章程》）的有关规定，经深圳华大基因股份有限公司（以下简称公 司）第四届董事会第七次会议审议通过，公司董事会决定于2025年11月12日（星 期三）召开公司2025年第二次临时股东会。现就本次会议有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东会 2、股东会召集人：公司董事会 3、会议召开的合法性及合规性：经公司第四届董事会第七次会议审议通过， 决定召开2025年第二次临时股东会，召集程序符合有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025年11月12日（星期三）14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年11月12日9:15-9:25， ...

证券代码：300676 证券简称：华大基因 公告编号：2025-055 深圳华大基因股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、深圳华大基因股份有限公司（以下简称公司）第四届监事会第七次会议 于2025年10月20日通过电子邮件形式送达至全体监事，通知中包括会议的相关材 料，同时列明了会议的召开时间、内容和方式。 2、本次监事会于2025年10月23日在公司会议室召开，以现场与通讯相结合 的方式进行表决（其中监事刘斯奇以通讯方式参加会议）。 3、本次监事会应参加表决监事3名，实际参加表决监事3名。 4、本次监事会由监事会主席刘斯奇先生召集和主持，公司董事会秘书和证 券事务代表列席了本次监事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《深圳华大基因股份有限公司章程》的有关规定。 二、监事会会议审议情况 《关于增加2025年度日常关联交易预计额度的公告》同日披露于巨潮资讯网。 表决结果：2票赞成，0票反对，0票弃权。 公司关联监事刘斯奇已对本议案回避 ...

2、本次董事会于2025年10月23日在公司会议室召开，以现场与通讯相结合 的方式进行表决（其中董事汪建、李宁、朱师达、张国成、杜兰、于李胜、侯志 波以通讯方式参加会议）。 3、本次董事会应参加表决董事9名，实际参加表决董事9名。 4、本次董事会由董事长汪建先生召集和主持，公司部分监事和高级管理人 员列席了本次董事会。 证券代码：300676 证券简称：华大基因 公告编号：2025-054 深圳华大基因股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、深圳华大基因股份有限公司（以下简称公司）第四届董事会第七次会议 于2025年10月20日通过电子邮件形式送达至全体董事，通知中包括会议的相关材 料，同时列明了会议的召开时间、内容和方式。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称《公司法》）等法律法规和《深圳华大基因股份有限公司章程》（以下简 称《公司章程》）的有关规定。 二、董事会会议审议情况 1、审议通过《关于2025年第三季度报告的议案》 与会董事审议认 ...

华大基因公告，第三季度营收为10.42亿元，同比增长9.19%；净利润亏损2716.52万元，下降80.92%。 前三季度营收为26.74亿元，同比下降5.39%；净利润亏损2138.7万元，下降82.78%。 ...

Financial Performance - The company's revenue for Q3 2025 was ¥1,042,166,389.29, representing a 9.19% increase compared to the same period last year[3] - The net profit attributable to shareholders was -¥27,165,209.53, a decrease of 80.92% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥36,276,537.39, a decrease of 74.17% compared to the previous year[3] - For the first three quarters of 2025, the company achieved operating revenue of RMB 267,363.87 million, a year-on-year decrease of 5.39%[15] - The net profit attributable to shareholders for the same period was RMB -2,138.70 million, an increase of 82.78% year-on-year[15] - In Q3 2025, the company reported operating revenue of RMB 104,216.64 million, a year-on-year growth of 9.19%[15] - Total revenue for the current period is ¥2,673,638,742.11, a decrease of 5.37% from ¥2,825,935,926.99 in the previous period[30] - The net profit for the current period is -26,230,892.14, compared to -124,180,426.78 in the previous period, showing a significant improvement[31] - Operating profit for the current period is -35,804,257.97, an improvement from -119,699,288.76 in the previous period[31] - Total comprehensive income for the current period is -63,301,430.15, compared to -154,305,996.91 in the previous period, reflecting a reduction in losses[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥12,301,377,285.05, down 1.92% from the end of the previous year[3] - Total current assets decreased to ¥6,530,214,262.62 from ¥6,875,791,256.55, reflecting a decline of 5.02%[28] - Total non-current assets increased to ¥5,771,163,022.43 from ¥5,666,495,138.08, showing a growth of 1.85%[28] - Total liabilities decreased to ¥2,929,583,566.20 from ¥3,270,676,576.56, a reduction of 10.43%[28] - The company's total equity increased to ¥9,371,793,718.85 from ¥9,271,609,818.07, reflecting a growth of 1.08%[29] Cash Flow - The company's cash flow from operating activities was -¥436,673,090.75, a decrease of 205.77% compared to the same period last year[3] - Cash flow from operating activities shows a net outflow of -436,673,090.75, compared to -142,812,352.08 in the previous period, indicating a worsening cash flow situation[32] - The company received cash from investment activities totaling 4,754,090,112.22, compared to 7,661,136,503.58 in the previous period, indicating a decrease in investment inflows[32] - The net cash flow from financing activities is 180,044,633.76, a recovery from -316,812,088.02 in the previous period[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 67,903[10] - As of the report date, the controlling shareholder, BGI Holdings, pledged 10.375 million shares, accounting for 79.18% of its holdings and 24.80% of the total share capital[20] - The shareholder, Shenzhen Shenghua Investment, reduced its holdings by 1.2507 million shares, representing 0.2990% of the total share capital, as part of a planned reduction of up to 6.2748 million shares[23] - BGI Holdings transferred 16.7327 million shares at a price of 44.10 yuan per share, totaling approximately 738 million yuan, reducing its stake from 38.17% to 31.32%[24] Business Segments - The reproductive health business generated operating revenue of RMB 643 million, down 28.4% compared to RMB 899 million in the same period of 2024[17] - The non-invasive prenatal genetic testing business saw a revenue decline of approximately 36% year-on-year[17] - Revenue from the hereditary disease clinical diagnosis series in the tertiary prevention business grew by approximately 17% year-on-year[17] - The oncology and chronic disease prevention business achieved revenue of 358 million yuan, a decrease of 8.8% compared to 393 million yuan in the same period of 2024[18] - The infection prevention business reported revenue of 75 million yuan, a year-on-year increase of 41.7% from 53 million yuan in 2024, driven by the development of a pathogen sequencing platform and automation systems[18] - The multi-omics and synthesis business generated revenue of 452 million yuan, remaining stable compared to the previous year, with single-cell sequencing revenue growing approximately 93%[18] - The precision medicine testing comprehensive solution business achieved revenue of 1.124 billion yuan, an increase of 11.2% from 1.010 billion yuan in 2024, due to accelerated local clinical application and successful overseas market expansion[19] Expenses - The sales expenses decreased by 17.73%, management expenses decreased by 17.76%, and R&D expenses decreased by 16.38% during the reporting period[15] - Research and development expenses decreased to ¥332,812,703.86, a reduction of 16.43% compared to ¥398,014,771.10 in the previous period[30] Other Financial Metrics - The basic earnings per share were -¥0.0653, an increase of 81.08% year-on-year[3] - The weighted average return on equity was -0.29%, an increase of 1.14% compared to the previous year[3] - The company recorded an increase of RMB 82.11 million in credit impairment losses compared to the same period last year due to extended customer payment cycles[16] - The company incurred a tax expense of -19,791,439.13, compared to -2,842,029.91 in the previous period, indicating a higher tax burden despite losses[31]

Core Insights - The gene synthesis industry is a subset of DNA synthesis, focusing on the artificial creation of long double-stranded DNA with specific sequences, which is crucial for synthetic biology [1][3] - The Chinese gene synthesis market is projected to reach approximately 14.3 billion yuan in 2023, reflecting significant growth driven by government support and technological advancements [1][5] - BGI Genomics, a leading company in the Chinese gene synthesis sector, has established a comprehensive marketing network and offers a wide range of gene synthesis services [5] Industry Overview - Gene synthesis involves the chemical or enzymatic methods to artificially create genes or specific DNA sequences, with applications in basic research, biotechnology, gene therapy, and synthetic biology [3] - The industry is increasingly supported by government policies, which have integrated synthetic biology into national strategic emerging industries, fostering innovation and providing a favorable environment for growth [1][5] Market Dynamics - The integration of gene editing technologies, standardization of gene components, and advancements in microbial chassis engineering are expected to enhance the application capabilities of gene synthesis [7] - The demand for gene synthesis in the pharmaceutical sector, particularly in gene therapy and vaccine development, is anticipated to grow significantly [7] Competitive Landscape - BGI Genomics is recognized as a pioneer in the Chinese gene synthesis industry, providing various services including optimized cDNA synthesis and gene mutation services [5] - The industry analysis employs various research models such as SCP, SWOT, and PEST to evaluate market conditions, policies, competition, and technological innovations [7] Future Outlook - The report forecasts the development trends of the gene synthesis industry in China from 2025 to 2031, focusing on driving factors, constraints, and demand prospects [15][16] - The ongoing integration of artificial intelligence and machine learning is expected to significantly reduce design times and enhance the precision and efficiency of gene synthesis methods [7]

Core Viewpoint - The launch of Genos, the world's first hundred billion parameter universal basic model for the human genome, represents a significant advancement in genomic research, transitioning from merely reading base sequences to understanding the underlying logic of life [1] Group 1: Product Development - Genos is a genome foundational model optimized for the human genome, capable of supporting ultra-long context analysis of up to one million base pairs [1] - The model achieves precise identification at single-base resolution, enhancing the accuracy of genomic analysis [1] Group 2: Impact on Industry - The introduction of Genos is expected to bring transformative changes to clinical disease diagnosis, personal genome interpretation, and cutting-edge scientific research [1] - The related findings have been published in the international academic journal GigaScience, indicating the model's credibility and relevance in the scientific community [1]